- Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry
- LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products
- Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications
Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as well as existing products and applications, and allows LXRP and stakeholders to participate, on a global scale, in the medical marijuana market that is expected to reach a value of USD $55.8 billion by 2025 according to a report by Grand View Research, Inc. (http://cnw.fm/E2yT5)
John Docherty, President of Lexaria Bioscience Corp., recently issued a video clip discussing the company’s innovative technology that allows for the enhanced flavor and faster absorption of edible products. He discussed opportunities LXRP stakeholders have in commercial applications via third-party licensing in order to leverage the innovative technology to improve delivery and performance of various products in a cost-effective manner (http://cnw.fm/DzN3f).
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer